ArrowMark Colorado Holdings’s NewAmsterdam Pharma NAMS Stock Holding History

ArrowMark Colorado Holdings’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.18M	Sell	211,843 -47,681	-18%	-$1.57M	0.3%	135
2026 Q1	$8.31M	Sell	259,524 -38,553	-13%	-$1.26M	0.22%	137
2025 Q4	$10.5M	Sell	298,077 -12,922	-4%	-$470K	0.23%	129
2025 Q3	$8.84M	Sell	310,999 -47,615	-13%	-$1.14M	0.16%	147
2025 Q2	$6.49M	Sell	358,614 -3,108	-0.9%	-$56.7K	0.12%	172
2025 Q1	$7.4M	Buy	361,722 +16,674	+5%	+$371K	0.12%	150
2024 Q4	$8.87M	Sell	345,048 -9,927	-3%	-$211K	0.12%	149
2024 Q3	$5.89M	Buy	354,975 +57,806	+19%	+$1M	0.08%	175
2024 Q2	$5.71M	Buy	297,169 +362	+0.1%	+$7.26K	0.07%	191
2024 Q1	$7.02M	Buy	+296,807	New	+$6.02M	0.08%	181

Other funds holding NAMS

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

DFO

Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

ArrowMark Colorado Holdings's NAMS Position: Q2 2026 in Review

ArrowMark Colorado Holdings reduced its NewAmsterdam Pharma (NAMS) stake by 18% in Q2 2026, selling an estimated $1.57M and leaving 211,843 shares worth $7.18M. The position accounts for 0.3% of the portfolio, ranked #135.

ArrowMark Colorado Holdings first reported a position in NAMS in Q1 2024 and has held it in 10 quarters since. The position peaked at $10.5M in Q4 2025. 195 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

ArrowMark Colorado Holdings held 211,843 shares of NewAmsterdam Pharma worth $7.18M as of Q2 2026.
ArrowMark Colorado Holdings sold 47,681 NewAmsterdam Pharma shares in Q2 2026, an estimated $1.57M.
NewAmsterdam Pharma made up 0.3% of ArrowMark Colorado Holdings's portfolio in Q2 2026, its #135 holding.
ArrowMark Colorado Holdings first reported a position in NewAmsterdam Pharma in Q1 2024 and has held it in 10 quarters since.
ArrowMark Colorado Holdings's NewAmsterdam Pharma position peaked at $10.5M in Q4 2025.
195 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on ArrowMark Colorado Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.